Anti-cancer targeting telomerase inhibitors: β-rubromycin and oleic acid

Yoshiyuki Mizushina1, Toshifumi Takeuchi, Fumio Sugawara

  • 1Laboratory of Food & Nutritional Sciences, Department of Nutritional Science, Kobe-Gakuin University, Kobe, Hyogo 651-2180, Japan. mizushin@nutr.kobegakuin.ac.jp

Insights

Researchers identified β-rubromycin and oleic acid as potent inhibitors of human telomerase. Their V-shaped structure and molecular length are key for inhibiting telomerase activity, suggesting potential for new cancer drug development.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Telomerase is crucial for cancer cell immortalization.
  • Identifying telomerase inhibitors is vital for cancer therapy.
  • Natural and chemical compounds are screened for inhibitory activity.

Purpose of the Study:

  • To screen for potent inhibitors of human telomerase.
  • To investigate the inhibitory mechanism and structural features of identified compounds.
  • To explore potential for developing novel telomerase inhibitors.

Main Methods:

  • Screening of natural and chemical compounds for telomerase inhibition.
  • Determination of IC(50) values for β-rubromycin and oleic acid.
  • Kinetic analysis of enzyme inhibition.
  • Energy-minimized 3D structure calculation and design.

Main Results:

  • β-rubromycin and oleic acid demonstrated potent inhibition of human telomerase (IC(50) values of 8.60 and 8.78 μM).
  • Inhibition was competitive with respect to primer and dNTP substrates.
  • A V-shaped structure and molecular length of 18.7-20.3 Å were identified as important features for inhibition.
  • A potential "pocket" in the telomerase active site may accommodate these inhibitors.

Conclusions:

  • β-rubromycin and oleic acid are effective competitive inhibitors of human telomerase.
  • Specific structural characteristics of these compounds are critical for their inhibitory function.
  • These findings provide a basis for designing more potent telomerase inhibitors for cancer treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...